N. Mobashery

Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)

Lai Wei, Guiqiang Wang, Negar N. Alami et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 54 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

P1345 : A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis

Tarik Asselah, Tarek Hassanein, R.B. Qaqish et al. · Journal of Hepatology · 2015 · 15 citations

Medicine, Pharmacology, Pharmacotherapy +16

High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis with Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin (AGATE-I)

Tarik Asselah, Christophe Hézode, R.B. Qaqish et al. · Journal of Hepatology · 2016 · 11 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17